Hong Kong · Sponsored
Abemaciclib: A review of the evidence through clinical cases
This content is sponsored. It is intended for healthcare professionals only.
Chemotherapy was the earliest available treatment and was the standard of care for patients with estrogen receptor positive (ER+), human epidermal growth factor 2 receptor negative (HER2-) metastatic breast cancer (mBC) some decades ago. Since the detection of ER in the 1980s and with the introduction of endocrine therapy (ET), ET has replaced chemotherapy as the standard of care for ER positive mBC. In a recent webinar, Professor Mark Verrill, Dr Roland Leung and Dr Adrian Tse discussed how the introduction of cyclin-dependent kinase 4&6 inhibitors (CDK4 & 6i) has revolutionised breast cancer
